Product Innovation and Population Dynamics in the German Insurance Market

Empirical research in organizational ecology has mainly focused on analyzing founding and mortality rates using life history data of the organizations. We try to extend this approach in our study in a number of ways. In contrast to most empirical studies in organizational ecology, we chose a population of service organizations, in particular the German insurance companies, the development dynamics of which are rather obvious in the innovative activities of existing organizations than in founding activities. We further discuss the points of contact between the organizational ecology approach and the theory of industry life cycles and extend the analysis to the relationship between innovative activities and population dynamics. The study examines the effects of population density, former events, and organizational size and age structure in the population of property & casualty insurance companies on the number of product innovations generated. We will further develop a concept for an insurance specific industry life cycle with a non-typical maturation and degeneration phase.service industries; population ecology; industry life cycles

Spin label EPR structural studies of the N-terminus of α-spectrin

AbstractSpectrin, a vital component in human erythrocyte, is composed of α- and β-subunits, which associate to form (αβ)2 tetramers. The tetramerization site is believed to involve the α-spectrin N-terminus and the β-spectrin C-terminus. Abnormal interactions in this region may lead to blood disorders. It has been proposed that both termini consist of partial structural domains and that tetramerization involves the association of these partial domains. We have studied the N-terminal region of a model peptide for α-spectrin by making a series of double spin-labeled peptides and studying their dipolar interaction by electron paramagnetic resonance methods. Our results indicate that residues 21–42 of the N-terminus region exhibit an α-helical conformation, even in the absence of β-spectrin

US-Schuldenkrise: Droht den USA ein Vertrauensverlust?

Angesichts der ungelösten Schuldenkrise in Europa geht Harm Bandholz, UniCredit Bank, New York, davon aus, dass die Investoren weiterhin auf Altbewährtes setzen und ihr Vertrauen in US-Staatsanleihen behalten müssen. Für Michael Menhart, Munich RE, bleiben Zweifel an der langfristigen Tragfähigkeit des amerikanischen Wachstumsmodells. Allerdings greife eine Fokussierung der Diskussion auf die USA in jedem Fall zu kurz. Für Josef Braml, Gesellschaft für Auswärtige Politik (DGAP), Berlin, werden die gesellschaftlichen und politischen Konflikte die wirtschaftlichen Probleme der USA verschärfen, während Bernd Weidensteiner, Commerzbank, Frankfurt am Main, trotz steigender Belastungen in den USA keine Schuldenkrise sieht. Nach Ansicht von Eckhard Janeba, Universität Mannheim, steckt hinter den Vertrauensproblemen in den USA eine ökonomische Schieflage, die das Vertrauen in die USA weiter schwinden lassen könnte.Öffentliche Schulden, Krise, Vertrauen, Wachstumstheorie, Vereinigte Staaten

FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials

Purpose Fluorine-18 fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG PET/CT) is the standard for staging aggressive non-Hodgkin lymphoma (NHL). Limited data from prospective studies is available to determine whether initial staging by FDG PET/CT provides treatment-relevant information of bone marrow (BM) involvement (BMI) and thus could spare BM biopsy (BMB). Methods Patients from PETAL (NCT00554164) and OPTIMAL>60 (NCT01478542) with aggressive B-cell NHL initially staged by FDG PET/CT and BMB were included in this pooled analysis. The reference standard to confirm BMI included a positive BMB and/or FDG PET/CT confirmed by targeted biopsy, complementary imaging (CT or magnetic resonance imaging), or concurrent disappearance of focal FDG-avid BM lesions with other lymphoma manifestations during immunochemotherapy. Results Among 930 patients, BMI was detected by BMB in 85 (prevalence 9%) and by FDG PET/CT in 185 (20%) cases, for a total of 221 cases (24%). All 185 PET-positive cases were true positive, and 709 of 745 PET-negative cases were true negative. For BMB and FDG PET/CT, sensitivity was 38% (95% confidence interval [CI]: 32–45%) and 84% (CI: 78–88%), specificity 100% (CI: 99–100%) and 100% (CI: 99–100%), positive predictive value 100% (CI: 96–100%) and 100% (CI: 98–100%), and negative predictive value 84% (CI: 81–86%) and 95% (CI: 93–97%), respectively. In all of the 36 PET-negative cases with confirmed BMI patients had other adverse factors according to IPI that precluded a change of standard treatment. Thus, the BMB would not have influenced the patient management. Conclusion In patients with aggressive B-cell NHL, routine BMB provides no critical staging information compared to FDG PET/CT and could therefore be omitted. Trial registration NCT00554164 and NCT0147854